April 24, 2017

MockV Solutions Announces Collaboration with Texcell N.A. to Assess MVP Technology

Rockville, MD – April 24, 2017 – MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today that it is partnering with Texcell North America, Inc. (Texcell N.A.) to assess its Mock Virus Particle (MVP) technology. The assessment will be conducted at Texcell N.A.'s headquarters in Frederick, Maryland and is designed to compare the removal of MockV's non-infectious MVM-MVP's to live Minute Virus of Mice (MVM) through a series of nanofiltration experiments.

Minute Virus of Mice (MVM), a small and physicochemical resistant parvovirus, is a universal standard for assessing viral clearance during process validation studies. Currently, assessments are made by spiking live infectious MVM into biopharmaceutical material, processing the material through a scaled down version of a manufacturing process step, quantifying MVM before and after processing and determining the removal efficiency of the challenged process step. To help facilitate the attainment of knowledge during bioprocess development, both Texcell and MockV are trying to provide novel solutions. MockV, through the pursuit of non-infectious MVP Kits and Texcell, through the offering of investigational studies which are quick and cost effective.

"This study will help determine if MVM-MVP's can accurately predict live MVM clearance through side by side MVM-MVP/live MVM spiking experiments", said MockV Founder and CEO David Cetlin. "We are excited to see our MVP's in action and anticipate the publication and presentation of our findings with Texcell as soon as data is available." "Our organization is also very excited to work with MockV to develop novel MVP methods that will potentially shorten critical timelines for biotherapeutic process development" stated Dr. Luke Pallansch, Scientific Director at Texcell – North America. "I believe this novel technology will be a powerful tool for Process Developers in the future and we look forward to demonstrating its feasibility in this regard."

About Texcell North America Inc.

Texcell N.A. is a Contract Service Organization (CSO) located in Frederick, MD that has specialized in GLP Viral Clearance studies since 2002. Texcell, headquarter in Evry, France, as a global organization has been providing R&D Cell Culture, cGMP Cell Bank Production & Testing, Viral Clearance and Viral Safety Testing for the biopharmaceutical industry since 1987. In 2015 operations expanded to include partners VIVO Sciences in Granau Germany, and ATRI in Taipei Taiwan offering clients even more locations to meet their testing and production needs.

Texcell N.A. is pleased to be the first CSO Biosafety provider to explore this potential additional Viral Clearance support service. We have been intimately involved with the development and validation of this kit and we could provide the high titer MVM stocks to have a comparative analysis between the "Mock MVM" and a live infectious virus. Texcell as an organization tries to be a proactive and innovative Biosafety partner in the industry.

For further information regarding Texcell N.A., please visit the Company's website at http://www.texcell.com/

About MockV Solutions Inc.

MockV Solutions, Inc. (MVS) is a biotechnology company commercializing non-infectious viral-surrogate tools to a variety of industries that currently rely on expensive and logistically challenging live virus analysis. MockV is developing a novel series of analytical assay kits which will enable biopharmaceutical process development scientists to study the efficacy of manufacturing techniques intended to remove or inactive virus, a contaminant of great concern during the manufacturing of biopharmaceuticals. These products are only approved for clinical or commercial use after their manufacturing processes demonstrate sufficient viral clearance. Currently, this is accomplished through the use of live mammalian model viruses (ex. MVM and XMuLV) in expensive and logistically challenging "spiking studies". The lack of economical and accurate means of analyzing viral clearance during small scale process development increases the risk of failing viral clearance regulatory requirements - jeopardizing the timely approval of potentially life-altering therapies. MockV's lead product candidate, the MVM_{MVP} Kit contains a non-infectious "Mock Virus Particle" (MVP) that mimics the physicochemical characteristics of live infectious MVM, as well as reagents and components to quantify MVP in solution. Currently, this business segment is supported by a $100,000 convertible note from the Technology Commercialization Fund of The Maryland Technology Development Corporation (TEDCO)

For further information regarding MockV Solutions, Inc., please visit the Company's website at www.mockvsolutions.com.